Revenue (Tables)

12 Months Ended

Dec. 31, 2018

Revenue Recognition and Deferred Revenue [Abstract]

Impact of ASC 606 in Current Period [Table Text Block]

The following tables represent the amounts by which each financial statement line item is affected in the current year as a result of applying ASC Topic 606 (in thousands):

	For the year ended December 31, 2018
	As Reported		Without Adoption of ASC 606		Effect of Adoption
Revenue	$	1,400,040	$	1,388,923	$	11,117
Cost of goods sold	$	830,012	$	826,607	$	3,405
Gross Profit	$	570,028	$	562,316	$	7,712

	As of December 31, 2018
	As Reported		Without Adoption of ASC Topic 606		Effect of Adoption
Prepaid expenses and other current assets	$	25,980	$	32,487	$	(6,507	)
Accrued liabilities	$	128,820	$	151,408	$	(22,588	)
Deferred income taxes	$	38,654	$	40,653	$	(1,999	)

Disaggregation of Revenue [Table Text Block]

The following table represents our revenues disaggregated by geography (in thousands):

	For the year ended December 31,
Geography	2018		2017 (1)		2016(1)
Europe, the Middle East and Africa	$	134,363	$	119,934	$	50,105
Other Foreign	210,996		192,640		67,573
Total Foreign	345,359		312,574		117,678
United States	1,054,681		980,039		261,694
Total Revenues	$	1,400,040	$	1,292,613	$	379,372

_______________________________

⁽¹⁾ As noted above, prior period amounts have not been adjusted under the modified retrospective method.

Domestic sales accounted for 75%, 76% and 69% of total revenue in 2018, 2017 and 2016, respectively. International sales accounted for 25%, 24% and 31% of total revenue in 2018, 2017 and 2016, respectively.

The following table represents our revenues disaggregated by product line (in thousands) and our disaggregated product line revenue as a percentage of total revenue:

	For the year ended December 31,
	2018				2017 (1)				2016(1)
Product line	Revenue		% of Revenue		Revenue		% of Revenue		Revenue		% of Revenue
Infusion Consumables	$	483,039	35	%	$	365,665	28	%	$	324,868	86	%
IV Solutions	507,985		36	%	521,963		40	%	—		—	%
Infusion Systems	355,484		25	%	290,207		23	%	—		—	%
Critical Care	53,532		4	%	49,961		4	%	53,601		14	%
Other	—		—	%	64,817		5	%	903		—	%
Total Revenues	$	1,400,040	100	%	$	1,292,613	100	%	$	379,372	100	%

_______________________________

⁽¹⁾ As noted above, prior period amounts have not been adjusted under the modified retrospective method.

Contract with Customer, Asset and Liability [Table Text Block]

Our contract balances (deferred revenue) are recorded in accrued liabilities and other long-term liabilities in our consolidated balance sheet (see Note 10, Accrued Liabilities). The following table presents our changes in the contract balances for the year ended December 31, 2018, (in thousands):

	Contract Liabilities
Beginning balance, January 1, 2018	$	(7,066	)
Equipment revenue recognized	6,696
Equipment revenue deferred due to implementation	(4,196		)
Software revenue recognized	6,553
Software revenue deferred due to implementation	(6,269		)
Ending balance, December 31, 2018	$	(4,282	)